WO2026062524 - COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/062524
Publication Date
26.03.2026
International Application No.
PCT/IB2025/059326
International Filing Date
17.09.2025
Title **
[English]
COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
[French]
ANTICORPS DE RÉCEPTEUR DU FACTEUR 1 DE STIMULATION DE COLONIES ET PROCÉDÉS D'UTILISATION ASSOCIÉS
Applicants **
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors
NISHIKORI, Shingo
MURJI, Amyn
BROSSI, Nicole
VISWANATHAN, Karthik
RAMAKRISHNAN, Ramki
WOODALL, Nicholas
WOLLACOTT, Andrew
YIN, Yizhou
BABCOCK, Gregory
KUROIWA, Yoshimi
OHMOTO, Koji
Priority Data
63/695,615
17.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5752 | |
| EPO | Filing, Examination, Granting | 114589 | |
| Japan | Filing, Examination, Granting | 4889 | |
| South Korea | Filing, Examination, Granting | 8297 | |
| USA | Filing, Examination, Granting | 25040 |
Total:
158,567
Contact Us
Abstract[English]
of pM to low nM) and therapeutic uses of such sdAbs in effectively treating CSF1R mediated diseases, such as age-related macular degeneration (AMD). In some embodiments, an anti-CSF1R sdAb is fused to an Fc region.[French]
de pM à faible nM) et des utilisations thérapeutiques de tels sdAbs dans le traitement efficace de maladies médiées par CSF1R, telles que la dégénérescence maculaire liée à l'âge (DMLA). Dans certains modes de réalisation, un sdAb anti-CSF1R est fusionné à une région Fc.